joi tirzepatide Microdose 22% body weight Tirzepatide Subscription - Joi +

According to clinical research, Mounjaro showed up to 22.5% weight loss in clinical trials, compared with the 15% average observed with Wegovy

These include: Heavier or lighter periods Spotting between periods Missed periods Shorter or longer cycles These reports are considered anecdotal

Examining the Evidence As of April 2024, there is no established clinical evidence linking Mounjaro (tirzepatide) directly to an increased risk of blood clots or venous thromboembolism

however, there were no significant changes in fasting insulin and insulin sensitivity index between groups [37]

There are some opportunities to improve on the current drugs, Campbell said